Recent clinical evaluations of Transurethral Microwave Thermotherapy (TUMT) using the Prostatron device and Prostasoft v2.5 software have demonstrated that while patients with benign prostatic hyperplasia (BPH) often report significant improvement in urinary symptoms following treatment, the procedure does not effectively alleviate the urinary obstruction linked to the condition.
Benign prostatic hyperplasia is a common urologic condition in aging men, characterized by enlargement of the prostate gland leading to urinary difficulties such as increased frequency, urgency, and weak stream. TUMT is a minimally invasive treatment designed to reduce prostate tissue through the application of microwave energy, theoretically relieving both symptoms and physical blockage.
However, findings suggest that, despite noticeable symptom improvement, the core obstruction remains unmitigated, limiting the clinical efficacy of TUMT in fully resolving the issues associated with BPH. This discrepancy highlights the need for thorough patient assessment and counseling prior to selecting this therapy.
Additionally, patients undergoing TUMT with the Prostatron system should be specifically warned about the potential occurrence of ejaculatory dysfunction, a side effect of the procedure. While not life-threatening, such side effects can impact quality of life and should be considered when weighing the benefits and risks.
These insights reinforce the importance of individualized treatment planning and informed consent, as well as the continued development and evaluation of BPH therapies that adequately address both symptomatic and anatomical aspects of the disease.
Source: https:// – Courtesy of the original publisher.
